ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
期權訓練營
投資學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
獎項與榮譽
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
抗疫概念
878.789
-11.619
-1.30%
手動刷新
漲家數:
3
跌家數:
14
平家數:
- -
市盈率:
- -
高:
889.460
開:
889.460
低:
870.070
收:
890.408
成交量:
3.01億
成交額:
22.54億
市值:
5,928.82億
流通市值:
4,916.77億
資料載入中...
總覽
新聞
獲利147萬元退繳150萬元 一醫藥代表因給予60萬元回扣被判刑
微博财经-财道工作室
·
09/01
港股開盤受壓 恒指低開0.59% 攜程集團-S(09961)跌2.56%
金吾财讯
·
09/01
恒瑞醫藥HER2 ADC三期數據積極,國產ADC一線治療競爭力提升|醫藥早參
每日经济新闻
·
09/01
迪哲醫藥(688192.SH):與阿斯利康就舒沃哲®授權許可協議生效
智通财经
·
09/01
【灣區早參】香港7月整體零售銷貨價值按年上升4.5%;藍皮書指2026年廣州經濟有望繼續保持穩定增長
金吾财讯
·
09/01
恒瑞醫藥ADC創新藥一項Ⅲ期臨床研究達到主要終點;力諾藥包籌劃赴港上市丨醫藥早參
每日经济新闻
·
09/01
新股消息 | 普萊醫藥二次遞表港交所
智通财经
·
09/01
歌禮制藥-B(01672)發布中期業績 股東應占虧損3.2億元 按年增加263.5%
智通财经
·
08/31
歌禮制藥-B:董事會建議不派發中期股息
美股速递
·
08/31
石藥集團(01093):SYH2092注射液用於成人超重或肥胖患者體重管理的I期臨床試驗在中國首個研究中心正式啓動
智通财经
·
08/31
石藥集團啓動SYH2092注射液中國體重管理I期臨床試驗
美股速递
·
08/31
中國生物製藥(01177)與Cipla就TQB2102訂立獨家授權協議
智通财经
·
08/31
中國生物製藥:有望獲得高達1.23億美元里程碑付款及分層雙位數特許權使用費
美股速递
·
08/31
中國生物製藥:Cipla獲Tqb2102印度、南非及五大市場獨家授權
美股速递
·
08/31
復星醫藥(02196)8月31日斥資113.02萬港元回購7.05萬股
智通财经
·
08/31
山東新華製藥股份(00719):阿奇黴素片通過仿製藥一致性評價
智通财经
·
08/31
港股異動 | 開拓藥業-B(09939)升逾5% 上半年虧損按年收窄 化妝品銷售帶動收入激增
智通财经
·
08/31
四環醫藥(00460)出現大手買入200萬股,成交價$0.76,涉資152萬
阿斯达克财经
·
08/31
比亞迪電子(00285)股價大幅波動17.771%,現價港幣$27.52
阿斯达克财经
·
08/31
中國貿促會:6月份全球經貿摩擦指數處於高位 衝突點聚焦電子、化工、醫藥等行業
同花顺
·
08/31
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BK1515/news?page=10"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"抗疫概念","latestPrice":878.7892,"timestamp":1789114133774,"preClose":890.4082,"halted":0,"volume":300625831,"delay":0,"changeRate":-0.013049,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-11.619019,"latestTime":"09-11 16:00:00","open":889.45984,"high":889.45984,"low":870.06995,"amount":2253603899,"amplitude":0.021776,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":1.318473,"peRate":17.086203,"turnoverRate":0.003644,"increases":3,"decrements":14,"flats":0,"marketCap":592881820352,"floatMarketCap":491676687872},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":889.45984,"amplitude":0.021776,"preClose":890.4082,"low":870.06995,"pbRate":"1.318473","latestPrice":878.7892,"volume":300625831,"delay":0,"open":889.45984,"prevYearClose":1190.107,"prevWeekClose":936.431,"prevMonthClose":925.265,"prevQuarterClose":802.777,"fiveDayClose":936.431,"twentyDayClose":912.416,"sixtyDayClose":852.523,"secType":"PLATE","market":"HK","turnoverRate":0.003644,"peRate":17.086203,"marketCap":592881820352,"floatMarketCap":491676687872,"timestamp":1789114133774,"nameCN":"抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":3,"down":14,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:10,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664822918","title":"獲利147萬元退繳150萬元 一醫藥代表因給予60萬元回扣被判刑","url":"https://stock-news.laohu8.com/highlight/detail?id=2664822918","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664822918?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 10:09","pubTimestamp":1788228540,"startTime":"0","endTime":"0","summary":"2026年5月8日,中国裁判文书网披露了一起医药代表因给予国家工作人员财物而被判刑的案例。经鉴定,被告人赵某向蕲春县某医院销售药品,共计获利201.8万元。2023年10月20日,被告人赵某自愿向蕲春县监委退缴全部违法所得150万元。2026年3月17日,湖北省蕲春县人民法院一审判决,赵某因以支付销售提成的方式给予国家工作人员财物60.0681万元,其行为构成行贿罪,判决赵某犯行贿罪,判刑1年3个月,缓刑2年,并处罚金10万元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2026-09-01/doc-iniqhsee1564812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PRTO","09939","BK1161","159938","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664488447","title":"港股開盤受壓 恒指低開0.59% 攜程集團-S(09961)跌2.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664488447","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664488447?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 09:27","pubTimestamp":1788226046,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股开盘受压,恒指低开0.59%,国企指数低开0.63%,恒生科技指数低开0.62%。惟云端业务自身毛利率已由去年同期的负0.4%转正至24.6%,并快速提升。石药集团低开1.19%,公司宣布,集团开发的SYH2092注射液用于成人超重或肥胖患者体重管理的I期临床试验已在中国首个研究中心正式启动。内地股市昨日上升,沪综指低开高走,收市上升0.9%,沪深两市成交额亦有所上升。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/YjFmNjZjNDg2MTA4NTI1ODgwMzI4.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YjFmNjZjNDg2MTA4NTI1ODgwMzI4.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990175","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0048597586.USD","LU0543330483.HKD","SG9999002463.SGD","LU0264606111.USD","LU0345769128.USD","LU0882747503.HKD","TCHmain","LU2362540622.SGD","LU2476274308.USD","LU2097828805.USD","ESPO","LU0043850808.USD","LU0918141887.USD","LU0531970944.HKD","LU0577902538.SGD","LU1323998911.USD","603993","BK1117","JEMA","LU0254981946.USD","LU0608807946.USD","IE00B031HY20.USD","LU1770036033.HKD","LU0541501648.USD","SG9999001051.SGD","HK0000306701.USD","SG9999015945.SGD","83115","LU1675838814.USD","LU1734074674.USD","LU1868837722.USD","LU0648000940.SGD","LU0499858602.USD","BK1601","BK1516","89888","02833","FFEM","SG9999011746.SGD","LU0862451753.SGD","LU1064130708.USD","LU1044876610.USD","LU2008162690.USD","IE0031814852.USD","IE0008368304.USD","LU0107464264.USD","LU1235295612.USD","HK0000914660.USD","GB00BDT5M118.USD","LU0210533765.USD","LU0588545904.SGD","LU0431992006.USD","LU2498475776.HKD","SG9999018865.SGD","LU0414403682.SGD","LU1044875133.USD","LU0823038988.USD","LU0456827905.SGD","LU0417516902.SGD","SG9999000459.SGD","LU0819121731.USD","LU2279858448.HKD","BK1229","LU0348805143.USD","LU0502904849.HKD","LU2317271919.USD","BK1586","LU1868837565.USD","LU1196710864.SGD","LU0499858438.USD","LU1439103000.SGD","LU0328353924.USD","BK1526","LU1642822792.SGD","BK1502","LU1282649067.USD","LU1981816686.USD","LU0417516571.SGD","LU1720051108.HKD","LU0650527681.SGD","BK1142","SG9999001846.SGD","HK0000306685.HKD","LU2251237488.HKD","LU0856984785.SGD","LU1974910355.USD","LU2279701549.SGD","IE00BHRH8C09.USD","HTCD.SI","GAMR","LU0165289439.USD","BK1588","603259","LU0543330566.HKD","LU0589944569.HKD","LU1316543674.SGD","81024","SG9999014674.SGD","LU0320764243.SGD","LU0261947096.USD","SGXZ62798434.SGD","LU0828238088.HKD","LU0072462343.USD","LU0169518387.USD","HK0000165453.HKD","LU2039709279.SGD","LU2237443978.SGD","LU0540923850.HKD","LU0828237510.HKD","TCEHY","LU0588545490.SGD","LU2226123227.USD","LU1051768304.USD","KURE","LU0047713382.USD","LU0762542818.HKD","IE00BZ08YR35.GBP","LU1303224171.USD","LU1917777945.USD","IE00BZ08YS42.EUR","SG9999014898.SGD","SG9999015952.SGD","IE00B031J352.USD","LU0455707207.USD","SG9999018857.SGD","HSTECH","LU0608807433.USD","LU0700851271.USD","SG9999014880.SGD","LU1769817096.USD","SG9999001903.USD","BK1191","BK1609","LU2242644610.SGD","LU0051755006.USD","LU1481107354.HKD","SG9999006597.SGD","LU0873338254.USD","LU0594300419.USD","IE00B0169L03.USD","LU0831103253.SGD","LU0868486357.SGD","LU0477156797.USD","LU1785774172.SGD","BK1190","FDNI","LU1794554557.SGD","LU1956131251.USD","LU2294711473.HKD","BK1576","LU0630378692.HKD","LU0488056044.USD","LU0561508036.HKD","LU1023057109.AUD","IE00B031HW06.USD","HK0000352382.USD","JADE","LU0231483743.USD","LU2399975544.HKD","AAXJ","LU0348814723.USD","LU0348766576.USD","LU0918141705.HKD","LU0128522157.USD","LU0572939691.SGD","LU2449936058.SGD","LU0203345920.USD","LU1048484197.HKD","02800","LU2148510915.USD","LU0823426308.USD","SG9999000327.SGD","LU1226288097.SGD","LU2097829019.USD","IE0032834883.USD","BK1164","LU2051468812.USD","LU0072913022.USD","HSI","01024","SG9999002562.SGD","CXSE","BK1610","LU0163747925.USD","LU1282651121.HKD","LU1568876335.HKD","SG9999004220.SGD","LU0067412154.USD","LU2097828631.EUR","SG9999001226.SGD","LU0228659784.USD","LU1810669033.SGD","09988","SG9999002828.SGD","LU0359201612.USD","LU1808992512.USD","IE00BPRC5H50.USD","LU2023250504.SGD","LU2177674079.SGD","LU0251143458.SGD","LU0048580855.USD","LU0345769631.USD","LU1688375341.USD","BK1141","IE00BMPRXR70.SGD","LU1115378108.SGD","LU0259732245.USD","LU0672654166.SGD","HHImain","LU1951186391.HKD","LU1629966141.USD","LU2293587155.HKD","LU0359202008.SGD","LU1880383440.USD","LU1316542783.SGD","LU2106854487.HKD","LU0516423174.USD","LU1224709979.USD","BABA","LU0651946864.USD","LU2097828474.EUR","LU1224444064.USD","IE00B543WZ88.USD","BIDU","BK1517","IE00B8HQ1Z84.USD","LU0228367735.SGD","LU2152927971.USD","LU0831093199.SGD","00700","LU0287142896.SGD","BK1115","IE00B29SXG58.USD","IE0003851619.USD","LU0164872284.USD","LU2778985437.USD","IE00B0169N27.USD","03115","LU1719994722.HKD","LU0261950983.USD","LU0106959298.USD","LU1188198961.HKD","LU2237443382.USD","LU2362541273.HKD","LU0469268626.HKD","LU0823397103.USD","SG9999017495.SGD","LU0143863784.USD","03419","SG9999015986.USD","LU0106259558.USD","LDEM","LU2237443549.SGD","LU0348735423.USD","LU1691799644.USD","LU1226287529.USD","LU0173614495.USD","LU0211977185.USD","LU2045819591.USD","LU0117844026.USD","LU1960683339.HKD","LU0127658192.USD","LU2187417386.USD","LU0501845795.SGD","LU0865486749.SGD","HK0001040168.HKD","LU2257852520.SGD","BKF","LU0828237940.HKD","LU0384037296.USD","MCHmain","LU0345775950.USD","LU0315178854.USD","SG9999003461.SGD","LU0359201885.HKD","LU0972618739.USD","SG9999001689.USD","BK1618","03037","HBBD.SI","LU0463099449.HKD","SOCL","LU1807302812.USD","01997","LU0143863198.USD","LU0516422440.USD","IE00BQXX3D17.EUR","LU0211331839.USD","LU2265009873.SGD","LU1880398471.USD","LU0594300179.USD","LU0786609619.USD","LU1046422090.SGD","IE00B97KM107.HKD","BK1575","IE0008368411.USD","LU0348783662.USD","LU1733274473.HKD","LU1282648689.USD","LU0029875118.USD","LU0049853897.USD","LU0348767384.USD","ALBmain","09961","BK1249","LU0396098781.USD","IE00B067MR52.USD","LU0605514214.HKD","LU1831875114.USD","LU0737861772.HKD","IE00BZ08YT58.USD","BK1521","LU0871576103.HKD","82800","IE0032431581.USD","LU0235996351.USD","LU1868838027.USD","LU0577902611.USD","LU1251922891.USD","LU0762540952.USD","LU2237443895.HKD","LU0675040207.SGD","LU1439102457.SGD","LU0348827113.USD","LU2929501877.USD","LU1515016050.SGD","LU0117841782.USD","07500","LU2362541513.USD","LU1961090484.USD","02359","06618","LU0588545730.USD","LU1196710351.USD","LU0516423091.SGD","IE00BF5LJ272.USD","LU0577902454.USD","LU0823041008.USD","LU1282649810.SGD","LU0708995153.HKD","LU0320764755.SGD","LU2424517915.HKD","LU2125910500.SGD","LU1226287792.SGD","LU2153591404.USD","LU3227948356.SGD","LU0149534421.HKD","LU1655091459.SGD","LU0164880469.USD","LU2251237306.USD","LU1366334578.USD","LU2488822045.USD","03993","LU1102505929.USD","LU0175139822.USD","LU1196710195.USD","LU0314109678.HKD","LU2097828714.EUR","LU0630378429.USD","LU0229494975.USD","SG9999000418.SGD","SG9999006514.SGD","LU0348825331.USD","BK1584","LU0449509016.USD","KSTmain","LU0531971595.HKD","LU0633140727.USD","LU0188438112.USD","LU0049112450.USD","SG9999013353.USD","LU0862451837.USD","LU1733274390.USD","LU0607220059.USD","LU1242518857.USD","BK1587","LU0516422952.EUR","ODDS","LU0441854154.USD","LU0516422366.SGD","LU0011963245.USD","SGXZ86797644.SGD","LU1770034418.SGD","LU0326950275.SGD","BK1591","LU0738912210.USD","LU1044874839.SGD","LU0029874905.USD","BK1247","IE00BMPRXN33.USD","IE00BQXX3C00.GBP","LU0417516738.SGD","SGXZ99366536.SGD","LU0164865239.USD","IE00BGV7N243.SGD","LU0269904917.USD","LU2237443622.USD","SG9999007991.SGD","LU1064131003.USD","86618","LU0683595622.HKD","LU0593848301.USD","IE0008368742.USD","LU0588546209.SGD","SGXZ51526630.SGD","LU2097828557.USD","BK1604","LU0821914370.USD","LU0823413587.USD","LU0784639295.USD","IE00BG0RBZ43.SGD","LU0181495838.USD","LU1048588211.SGD","LU0886674414.USD","LU1328277881.USD","LU0070217475.USD","LU0293314216.USD","HK0000151867.HKD","LU2476274720.SGD","LU0572944931.SGD","BK1515","TCHI","LU0132412106.USD","LU0348788117.USD","LU0197773673.USD","LU0577902298.EUR","LU1152091168.USD","LU0823039010.USD","IE00B5MMRT66.SGD","LU0251144936.SGD","LU1105468828.SGD","LU2237443465.HKD","89988","LU0329678337.USD","LU0572940350.SGD","LU0634319403.HKD","LU1102505762.USD","SBHMY","BK1590","LU0214875030.USD","LU1880383366.USD","LU1242518931.SGD","LU0096374516.USD","LU2351347302.SGD","LU0210527791.USD","SGXZ90724238.SGD","DRGN","LU0823413660.USD","LU1883866441.USD","LU2462611646.USD","LU1769817179.HKD","LU0244354667.USD","LU2133065610.SGD","XSOE","BK1500","IE00B3M56506.USD","LU0985320562.USD","LU0307460666.USD","SGXZ81514606.USD","KWEB","MAWHY","HK0000286598.CNH","LU1720050803.USD","BK1615","LU2357305700.SGD","EMC","LU0648948544.HKD","IE0003795394.USD","SG9999001069.SGD","LU0054450605.USD","LU1880398554.USD","LU1171460220.USD","LU2226123490.SGD","IE0034224299.USD","LU0651947912.USD","EEMX","HK0001040143.USD","LU0797268264.HKD","LU0577902371.SGD","LU0791591158.USD","LU1282651048.USD","LU0327786744.USD","LU1718418525.SGD","LU0203347892.USD","LU1226288253.USD","LU1048596156.SGD","BK1501","LU0048388663.USD","LU1548497426.USD","01177","LU0348816934.USD","SG9999004311.SGD","LU1328615791.USD","LU0326948709.USD","LU0229945570.USD","IE00B0JY6N72.USD","LU1282649141.HKD","09115","02513","BK1531","LU1568876251.USD","BK1571","LU0197773160.USD","SG9999014914.USD","LU0823040885.USD","LU0791590937.USD","BK1589","BK1594","LU0084288322.USD","HK0000320264.USD","LU1051769294.HKD","LU1813983027.USD","01999","LU1720051017.SGD","LU0642271901.SGD","LU0370786039.SGD","LU0080751232.USD","LU0880133367.SGD","LU0878005551.USD","HK0000352291.HKD","LU0823397285.USD","LU0192582467.USD","LU3063872942.SGD","LU0039217434.USD","LU0819123356.HKD","SG9999001093.SGD","IE0008369823.USD","LU0130518102.USD","LU0541502299.USD","BK1534","LU0890818403.SGD","LU0979878070.USD","LU0456842615.SGD","LU1226287875.USD","IE0003895053.USD","LU0509642566.USD","LU0140636845.USD","LU1814569148.SGD","IE0009570106.USD","TCOM","IE0001KFT4U8.USD","LU0348783233.USD","BK1583","LU0054237671.USD","IE00B8L5B284.USD","LU0149721374.USD","LU1211504680.USD","LU1366334651.USD","SGXZ31699556.SGD","LU0315179316.USD","SG9999014906.USD","BIDD","LU2125910849.SGD","HK0000320223.HKD","LU1201861165.SGD","LU1008478684.HKD","LU1226288170.HKD","LU0289960550.SGD","LU0633140560.USD","LU1993786604.SGD","LU0128522744.USD","LU1804176565.USD","EMCS","LU0196878994.USD","BK1095","LU0611395673.USD","LU0456846285.SGD","LU0823426480.USD","LU0348723411.USD","01093","LU0737861699.HKD","LU2087589342.USD","LU0061477393.USD","LU1725190679.HKD","LU0106252389.USD","513600","BK1608","LU0130103400.USD","LU0762541174.USD","LU1152091754.HKD","HK0000107257.USD","LU0348784397.USD","LU2348773727.SGD","LU0048575426.USD","LU0640798160.USD","LU0052750758.USD","BK1258","LU0449515922.USD","LU0210526637.USD","LU0261950470.USD","SG9999000475.SGD","LU1504937902.USD","LU2213484517.USD","HK0000914686.HKD","BK1592","IE00BHRH8D16.HKD","LU0878004406.USD","07300","LU0329678170.USD","LU0708995583.HKD","LU0898667661.SGD","07200","LU0320764599.SGD","IE00BQXX3F31.USD","LU2247934214.USD","09888","LU0345776255.USD","LU2226246903.HKD","SG9999015978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664884462","title":"恒瑞醫藥HER2 ADC三期數據積極,國產ADC一線治療競爭力提升|醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2664884462","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664884462?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 09:23","pubTimestamp":1788225791,"startTime":"0","endTime":"0","summary":"截至8月31日收盘,三大指数集体收涨,医药板块集体调整。医药ETF(512120)跟踪指数下跌1.46%,生物医药ETF(159508)跟踪指数下跌1.4%,港股通生物科技ETF(159102)跟踪指数下跌3.61%。相关个股中,泰格医药上涨5.9%,云南白药上涨0.78%,沃森生物下跌4.83%,长春高新下跌3.58%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013860997079.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013860997079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK0239","LU1255011170.USD","LU2097828557.USD","LU1064131003.USD","LU2097828805.USD","BK0028","LU2495084118.USD","159938","LU1655091616.SGD","LU2580892862.HKD","LU0359201885.HKD","LU1064130708.USD","LU1997245094.SGD","BK1515","LU0359201612.USD","LU2328871848.SGD","LU2097828631.EUR","LU2097828474.EUR","LU1969619763.USD","LU1997244956.HKD","BK1191","BK0188","LU0405327494.USD","LU2488822045.USD","BK1161","LU2543165471.USD","LU1781817850.SGD","09939","600276","LU2580892789.USD","LU0405327148.USD","LU0359202008.SGD","LU1146622755.USD","LU2289578879.USD","BK0196","BK0012","LU2097828714.EUR","BK0183","LU1328615791.USD","LU1820825898.SGD","LU2148510915.USD","LU1580142542.USD","LU1997245177.USD","BK0060","LU1023057109.AUD","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881161","title":"迪哲醫藥(688192.SH):與阿斯利康就舒沃哲®授權許可協議生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881161","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881161?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 08:44","pubTimestamp":1788223497,"startTime":"0","endTime":"0","summary":"智通财经APP讯,迪哲医药(688192.SH)发布公告,公司于2026年7月14日与AstraZeneca UK Limited(以下简称“阿斯利康”)签署《许可协议》,授予阿斯利康在全球范围内独家开发、商业化舒沃哲®的权利。协议约定的协议生效条件已全部满足,协议于2026年8月31日正式生效。阿斯利康将于今年第四季度在美国实现舒沃哲®商业化。公司将获得阿斯利康支付的一次性、不可返还的首付款6亿美元,最高达4 亿美元的临床开发里程碑款项以及最高达5亿美元的销售里程碑款项,此外公司将获得按舒沃哲®全球销售额最高到低双位数的阶梯式比例的特许权使用费。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","159938","BK1574","BK1161","BK1515","688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881609","title":"【灣區早參】香港7月整體零售銷貨價值按年上升4.5%;藍皮書指2026年廣州經濟有望繼續保持穩定增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881609","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881609?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 08:40","pubTimestamp":1788223225,"startTime":"0","endTime":"0","summary":"蓝皮书显示,2026年广州经济有望继续保持稳定增长,同比增速预计处于5.0%至6.2%区间。蓝皮书指出,2025年广州经济总体平稳运行,实现地区生产总值32039.46亿元,同比增长4.0%。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZTRlMTU1ZDUyYWE0NDQzMjc2MzgzOTI4MA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990154","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","01093","LU0072913022.USD","LU1226288170.HKD","LU0314109678.HKD","BK1500","IE00B543WZ88.USD","LU0315179316.USD","BK1117","IE0008368742.USD","BK1241","LU1226287792.SGD","BK1521","02513","LU1807302812.USD","LU1813983027.USD","LU1008478684.HKD","CYB","LU1951186391.HKD","IE00B5MMRT66.SGD","BK1191","BK1555","LU1152091754.HKD","UCmain","BK1240","03383","01999","IE00B031HY20.USD","LU1328277881.USD","LU0880133367.SGD","IE00BZ08YT58.USD","LU0140636845.USD","CNHmain","IE00BZ08YS42.EUR","LU1152091168.USD","LU1226287875.USD","LU0593848301.USD","IE00BZ08YR35.GBP","SG9999004220.SGD","LU1993786604.SGD","HK0000165453.HKD","LU0067412154.USD","BK1115","BK1515","02255","KURE","LU0326950275.SGD","BK1589","LU1960683339.HKD","LU1226287529.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664886163","title":"恒瑞醫藥ADC創新藥一項Ⅲ期臨床研究達到主要終點;力諾藥包籌劃赴港上市丨醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2664886163","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664886163?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 07:02","pubTimestamp":1788217348,"startTime":"0","endTime":"0","summary":"恒瑞医药ADC创新药一项Ⅲ期临床研究达到主要终点;力诺药包筹划赴港上市丨医药早参","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013860561844.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013860561844.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","IBBQ","150130","MEDX","06978","159938","BK0235","301188","BK1161","BK1515","BK1574","LNGR","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664886895","title":"新股消息 | 普萊醫藥二次遞表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2664886895","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664886895?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 06:34","pubTimestamp":1788215697,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","09939","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663006583","title":"歌禮制藥-B(01672)發布中期業績 股東應占虧損3.2億元 按年增加263.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663006583","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663006583?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 21:24","pubTimestamp":1788182651,"startTime":"0","endTime":"0","summary":"智通财经APP讯,歌礼制药-B 发布截至2026年6月30日止六个月业绩,该集团取得收入总额人民币5297.9万元,同比减少48.9%;研发成本3.42亿元,同比增加132.7%;公司权益股东应占亏损3.2亿元,同比增加263.5%;每股亏损30.74分。人体数据表明,ASC50有望成为同类首创及同类最佳口服小分子IL-17A抑制剂。ASC51为一款强效、选择性及每日一次口服STAT6降解剂并已具备向FDA 提交IND申请条件的候选药物。ASC52有望成为同类最佳IL-17AA、AF及FF口服环肽拮抗剂,预计将于2026年第四季度向FDA递交IND。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01672","01477","BK1161","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162031632","title":"歌禮制藥-B:董事會建議不派發中期股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1162031632","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162031632?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 21:18","pubTimestamp":1788182334,"startTime":"0","endTime":"0","summary":"歌礼制药-B(01672.HK)宣布,其董事会已决定不建议就中期业绩派发任何股息。这一决定反映出公司在当前阶段的财务策略与资本配置考量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01672","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663008368","title":"石藥集團(01093):SYH2092注射液用於成人超重或肥胖患者體重管理的I期臨床試驗在中國首個研究中心正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2663008368","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663008368?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 19:58","pubTimestamp":1788177490,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药集团 发布公告,集团开发的SYH2092注射液用于成人超重或肥胖患者体重管理的I期临床试验已在中国首个研究中心正式启动。集团已于2026年8月获得中国国家药品监督管理局就该产品签发的药物临床试验批准通知书,并于获批后启动该产品的I期临床试验。本次启动的I期临床试验旨在评价该产品在健康参与者中单次给药的安全性、耐受性、药代动力学和药效学的临床试验。该I期临床试验的参与者招募和筛选工作正在积极推进中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489745.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2039709279.SGD","01093","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU0501845795.SGD","IE0008368742.USD","LU1226288170.HKD","PSYK","MDTX","IE00B031HY20.USD","LU0326950275.SGD","LU0140636845.USD","LU1152091168.USD","LU1993786604.SGD","BK1515","IBBQ","BMED","LU1152091754.HKD","LU1226287529.USD","LU1226288253.USD","LU1328277881.USD","IBBJ","IE0008369823.USD","LU1813983027.USD","IE00B5MMRT66.SGD","LU0314109678.HKD","BK1521","LU1226287792.SGD","IE00B543WZ88.USD","LU0315179316.USD","LU0072913022.USD","LU1226287875.USD","BK1191","IE00BZ08YS42.EUR","LU1807302812.USD","KURE","SG9999004220.SGD","LU1008478684.HKD","LU1951186391.HKD","LU0880133367.SGD","LU1960683339.HKD","LU0067412154.USD","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136656281","title":"石藥集團啓動SYH2092注射液中國體重管理I期臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1136656281","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136656281?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 19:53","pubTimestamp":1788177190,"startTime":"0","endTime":"0","summary":"石药集团近日宣布,已在中国正式启动SYH2092注射液的I期临床试验,该试验旨在评估其在体重管理领域的应用潜力。\n据悉,这项临床研究将重点考察SYH2092注射液的安全性、耐受性及药代动力学特征,为后续的临床开发奠定基础。\n作为一家专注于创新药物研发的制药企业,石药集团正在积极推进其代谢疾病领域的管线布局。此次SYH2092注射液的临床试验启动,也标志着该公司在体重管理这一热门赛道上的又一重要进展。\n业内分析人士指出,随着全球肥胖人口持续攀升,体重管理药物市场正迎来前所未有的发展机遇。石药集团此举无疑将进一步丰富其在该领域的产品储备,有望在未来竞争中占据有利位置。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0067412154.USD","BK1191","LU1993786604.SGD","01093","IE00B543WZ88.USD","LU0315179316.USD","LU0314109678.HKD","LU0140636845.USD","LU1226287792.SGD","SG9999004220.SGD","BK1521","LU1951186391.HKD","LU1152091168.USD","IE00BZ08YT58.USD","LU1008478684.HKD","LU0072913022.USD","LU0326950275.SGD","LU1152091754.HKD","IE00B5MMRT66.SGD","LU2039709279.SGD","HK0000165453.HKD","LU1226288170.HKD","LU1226287875.USD","LU0501845795.SGD","BK1515","KURE","LU1226288253.USD","LU0880133367.SGD","LU1328277881.USD","LU1807302812.USD","IE0008368742.USD","LU1813983027.USD","IE0008369823.USD","LU1960683339.HKD","LU1226287529.USD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663721600","title":"中國生物製藥(01177)與Cipla就TQB2102訂立獨家授權協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2663721600","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663721600?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 18:45","pubTimestamp":1788173143,"startTime":"0","endTime":"0","summary":"智通财经APP讯,中国生物制药 发布公告,本集团附属公司正大天晴药业集团股份有限公司已与Cipla Limited就本集团自主研发的HER2双抗ADC订立独家授权与供应协议(协议)。这是TQB2102达成的第二项区域授权合作。Cipla将负责授权区域内的本地临床开发、注册申报及商业化,正大天晴将继续负责TQB2102的生产及供应。Cipla在印度、南非及其他新兴市场深耕多年,拥有成熟的注册、医学及商业化体系,为加速TQB2102在授权区域内的开发和商业化奠定了坚实基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药(01177)与Cipla就TQB2102订立独家授权协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","HK0000165453.HKD","BK1521","IE00BZ08YS42.EUR","BK1589","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1515","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128741165","title":"中國生物製藥:有望獲得高達1.23億美元里程碑付款及分層雙位數特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1128741165","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128741165?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 18:40","pubTimestamp":1788172814,"startTime":"0","endTime":"0","summary":"中国生物制药集团披露了一项重磅利好——该公司将有资格收取最高达1.23亿美元的里程碑付款,并可享受分层式、双位数的特许权使用费分成。与此同时,分层双位数的特许权使用费结构,则意味着随着产品净销售额的阶梯式增长,集团所能分得的收益比例也将相应提升,从而在商业化放量阶段持续贡献可观的经常性收入。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","BK1521","BK1515","BK1589","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1191","HK0000165453.HKD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171540168","title":"中國生物製藥:Cipla獲Tqb2102印度、南非及五大市場獨家授權","url":"https://stock-news.laohu8.com/highlight/detail?id=1171540168","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171540168?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 18:40","pubTimestamp":1788172810,"startTime":"0","endTime":"0","summary":"中国生物制药宣布,其旗下产品Tqb2102已授予Cipla独家许可,覆盖印度、南非以及另外五个关键市场。这一战略合作显著拓宽了该药物的海外商业版图,为中国生物制药的全球化布局再添重要砝码。据悉,此次授权涉及的市场范围广泛,不仅包括南亚次大陆的核心区域,还延伸至非洲大陆的重要经济体。通过携手Cipla,中国生物制药旨在借助其在上述地区的成熟销售网络与本地化运营经验,加速推进Tqb2102的商业化进程。此举亦被视为中国创新药企加速“出海”、深度参与国际医药市场竞争的又一缩影。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177","BK1521","BK1515","IE00BZ08YR35.GBP","BK1191","BK1589","HK0000165453.HKD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663079796","title":"復星醫藥(02196)8月31日斥資113.02萬港元回購7.05萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2663079796","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663079796?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 17:43","pubTimestamp":1788169397,"startTime":"0","endTime":"0","summary":"智通财经APP讯,复星医药(02196)发布公告,于2026年8月31日斥资113.02万港元回购7.05万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489530.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600196","02196","BK0239","BK1191","BK0175","BK0188","BK0096","BK1515","BK0183","BK1593","BK0012","BK0060","BK0028","BK0187","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663075527","title":"山東新華製藥股份(00719):阿奇黴素片通過仿製藥一致性評價","url":"https://stock-news.laohu8.com/highlight/detail?id=2663075527","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663075527?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 16:39","pubTimestamp":1788165582,"startTime":"0","endTime":"0","summary":"智通财经APP讯,山东新华制药股份 发布公告,近日,山东新华制药股份有限公司之全资子公司山东淄博新达制药有限公司收到国家药品监督管理局核准签发的阿奇霉素片《药品补充申请批准通知书》,该产品通过仿制药质量和疗效一致性评价。根据相关统计数据,2025年中国公立医疗机构阿奇霉素片销售额约为人民币6.7亿元。新达制药的阿奇霉素片于2026年8月通过仿制药质量与疗效一致性评价,有利于进一步提升市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","00719"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663078277","title":"港股異動 | 開拓藥業-B(09939)升逾5% 上半年虧損按年收窄 化妝品銷售帶動收入激增","url":"https://stock-news.laohu8.com/highlight/detail?id=2663078277","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663078277?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 15:44","pubTimestamp":1788162244,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,开拓药业-B(09939)涨超5%,截至发稿,涨5.56%,报1.71港元,成交额365.81万港元。消息面上,开拓药业2026年中期业绩显示,收益由去年同期600万元增至截至2026年6月30日止六个月的5200万元,净亏损7578.2万元,同比减少8.99%。公告称,收益增加主要由于直播电商销售带动新高端化妆品品牌KOSHINÉ(其主要成分KX-826为公司的核心产品之一)的全球销售。净亏损减少主要由于研发成本减少,部分被主要因营销及推广开支增加导致销售及营销开支增加所抵销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","BK4588","09939","BK4585","VXUS","KCAI","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663078074","title":"四環醫藥(00460)出現大手買入200萬股,成交價$0.76,涉資152萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2663078074","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663078074?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 15:40","pubTimestamp":1788162000,"startTime":"0","endTime":"0","summary":"[大手成交]四环医药(00460)在下午03:40出现大手买入,成交量为200万,成交价为港币$0.76,涉资152万。至目前为止,股价跌3.205%,今日最高价为$0.775,而最低价为$0.74,总成交量为7.409千万股,总成交金额港币$5.575千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2608315989/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2608315989/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1593","BK1600","BK1515","BK1191","00460"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663078101","title":"比亞迪電子(00285)股價大幅波動17.771%,現價港幣$27.52","url":"https://stock-news.laohu8.com/highlight/detail?id=2663078101","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663078101?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 15:25","pubTimestamp":1788161100,"startTime":"0","endTime":"0","summary":"[异动股]比亚迪电子(00285) 股价在下午03:25出现大幅波动17.771%,现股价为港币$27.52,比前收市价上升11.147%。至目前为止,今日最高价为$27.52,而最低价为$23.12。总成交量为5.344千万股,总成交金额为港币$13.795亿。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205154958317_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205154958317_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAC260831191/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAC260831191/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK1167","BK1607","BK1589","LU0348767384.USD","LU0274383008.USD","BK1540","BK1582","BK1149","LU0348766576.USD","BK1580","00285","BK1504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663665078","title":"中國貿促會:6月份全球經貿摩擦指數處於高位 衝突點聚焦電子、化工、醫藥等行業","url":"https://stock-news.laohu8.com/highlight/detail?id=2663665078","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663665078?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 15:19","pubTimestamp":1788160740,"startTime":"0","endTime":"0","summary":"8月31日,中国贸促会举行8月例行新闻发布会,新闻发言人就全球经贸摩擦指数、促进上合组织工商界交流与合作等热点话题进行了回应。中国贸促会新闻发言人杨帆表示,从综合指数看,2026年6月 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260831/c679442975.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260831/c679442975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK1574","BK1515","BK1161","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":10,"totalSize":219,"code":"91000000","status":"200"}]}}